Sittner & Nelson’s Sarepta Therapeutics SRPT Stock Holding History

Sittner & Nelson’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35K	Hold	75	–	–	﹤0.01%	555
2026 Q1	$1.63K	Hold	75	–	–	﹤0.01%	524
2025 Q4	$1.39K	Hold	75	–	–	﹤0.01%	492
2025 Q3	$1.45K	Hold	75	–	–	﹤0.01%	455
2025 Q2	$1.28K	Hold	75	–	–	﹤0.01%	464
2025 Q1	$4.79K	Hold	75	–	–	﹤0.01%	405
2024 Q4	$9.12K	Hold	75	–	–	﹤0.01%	356
2024 Q3	$9.37K	Hold	75	–	–	﹤0.01%	348
2024 Q2	$11.8K	Hold	75	–	–	0.01%	334
2024 Q1	$9.71K	Hold	75	–	–	﹤0.01%	346
2023 Q4	$7.23K	Hold	75	–	–	﹤0.01%	366
2023 Q3	$9.09K	Hold	75	–	–	0.01%	347
2023 Q2	$8.59K	Buy	75 +25	+50%	+$3.22K	﹤0.01%	353
2023 Q1	$6.89K	Hold	50	–	–	﹤0.01%	381
2022 Q4	$6.48K	Hold	50	–	–	﹤0.01%	373
2022 Q3	$6K	Hold	50	–	–	﹤0.01%	374
2022 Q2	$4K	Hold	50	–	–	﹤0.01%	424
2022 Q1	$4K	Hold	50	–	–	﹤0.01%	397
2021 Q4	$5K	Hold	50	–	–	﹤0.01%	385
2021 Q3	$5K	Hold	50	–	–	﹤0.01%	358
2021 Q2	$4K	Hold	50	–	–	﹤0.01%	346
2021 Q1	$4K	Hold	50	–	–	﹤0.01%	348
2020 Q4	$9K	Buy	+50	New	+$7.41K	0.01%	294

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Sittner & Nelson's SRPT Position: Q2 2026 in Review

Sittner & Nelson held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 75 shares worth $1.35K. The position accounts for ﹤0.01% of the portfolio, ranked #555.

Sittner & Nelson first reported a position in SRPT in Q4 2020 and has held it in 23 quarters since. The position peaked at $11.8K in Q2 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Sittner & Nelson held 75 shares of Sarepta Therapeutics worth $1.35K as of Q2 2026.
Sittner & Nelson left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Sittner & Nelson's portfolio in Q2 2026, its #555 holding.
Sittner & Nelson first reported a position in Sarepta Therapeutics in Q4 2020 and has held it in 23 quarters since.
Sittner & Nelson's Sarepta Therapeutics position peaked at $11.8K in Q2 2024.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Sittner & Nelson's 13F filing for Q2 2026, filed 7 Aug 2026.